287 related articles for article (PubMed ID: 38243752)
1. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
[TBL] [Abstract][Full Text] [Related]
2. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Brown E; Dynowski K; Wilk K; Li Y; Mathur V; Warsi QA; Wagman RB; Johnson NP
Lancet; 2022 Jun; 399(10343):2267-2279. PubMed ID: 35717987
[TBL] [Abstract][Full Text] [Related]
3. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
Blair HA
Drugs; 2024 Apr; 84(4):449-457. PubMed ID: 38592603
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
D'Hooghe T; Fukaya T; Osuga Y; Besuyen R; López B; Holtkamp GM; Miyazaki K; Skillern L
Hum Reprod; 2019 May; 34(5):813-823. PubMed ID: 31067329
[TBL] [Abstract][Full Text] [Related]
5. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
Diamond MP; Stewart EA; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod Open; 2019; 2019(4):hoz027. PubMed ID: 31777761
[TBL] [Abstract][Full Text] [Related]
6. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
BMC Womens Health; 2021 Jun; 21(1):250. PubMed ID: 34154590
[TBL] [Abstract][Full Text] [Related]
7. ESHRE guideline: endometriosis.
Becker CM; Bokor A; Heikinheimo O; Horne A; Jansen F; Kiesel L; King K; Kvaskoff M; Nap A; Petersen K; Saridogan E; Tomassetti C; van Hanegem N; Vulliemoz N; Vermeulen N;
Hum Reprod Open; 2022; 2022(2):hoac009. PubMed ID: 35350465
[TBL] [Abstract][Full Text] [Related]
8. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
10. Top 10 priorities for future infertility research: an international consensus development study† ‡.
Duffy JMN; Adamson GD; Benson E; Bhattacharya S; Bhattacharya S; Bofill M; Brian K; Collura B; Curtis C; Evers JLH; Farquharson RG; Fincham A; Franik S; Giudice LC; Glanville E; Hickey M; Horne AW; Hull ML; Johnson NP; Jordan V; Khalaf Y; Knijnenburg JML; Legro RS; Lensen S; MacKenzie J; Mavrelos D; Mol BW; Morbeck DE; Nagels H; Ng EHY; Niederberger C; Otter AS; Puscasiu L; Rautakallio-Hokkanen S; Sadler L; Sarris I; Showell M; Stewart J; Strandell A; Strawbridge C; Vail A; van Wely M; Vercoe M; Vuong NL; Wang AY; Wang R; Wilkinson J; Wong K; Wong TY; Farquhar CM; ; AlAhwany H; Balaban O; Barton F; Beebeejaun Y; Boivin J; Bosteels JJA; Calhaz-Jorge C; D’Angelo A; F. Dann L; J. De Jonge C; du Mez E; A. Ferriani R; Gerval MO; J. Gingel L; Greenblatt EM; Hartshorne G; Helliwell C; Hughes LJ; Jo J; Jovanović J; Kiesel L; Kietpeerakool C; Kostova E; Kucuk T; Kumar R; Lawrence RL; Lee N; Lindemann KE; Loto OM; Lutjen PJ; MacKinven M; Mascarenhas M; McLaughlin H; Mourad SM; Nguyen LK; Norman RJ; Olic M; Overfield KL; Parker-Harris M; Repping S; Rizzo R; Salacone P; Saunders CH; Sengupta R; Sfontouris IA; Silverman NR; Torrance HL; Uphoff EP; Wakeman SA; Wischmann T; Woodward BJ; Youssef MA
Hum Reprod; 2020 Dec; 35(12):2715-2724. PubMed ID: 33252677
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
[TBL] [Abstract][Full Text] [Related]
12. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
Obstet Gynecol; 2022 Dec; 140(6):920-930. PubMed ID: 36357960
[TBL] [Abstract][Full Text] [Related]
13. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS
Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383
[TBL] [Abstract][Full Text] [Related]
14. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
Stewart EA; Lukes AS; Venturella R; Arjona Ferreira JC; Li Y; Hunsche E; Wagman RB; Al-Hendy A
Obstet Gynecol; 2022 Jun; 139(6):1070-1081. PubMed ID: 35675604
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis.
Pokrzywinski RM; Soliman AM; Snabes MC; Chen J; Taylor HS; Coyne KS
Fertil Steril; 2021 Feb; 115(2):423-430. PubMed ID: 33066973
[TBL] [Abstract][Full Text] [Related]
16. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
17. A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis.
Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Dynowski K; Wilk K; Li Y; Mathur V; Wagman RB; Johnson NP
Pain Manag; 2023 Nov; 13(11):631-640. PubMed ID: 37982388
[TBL] [Abstract][Full Text] [Related]
18. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
Fertil Steril; 2021 Feb; 115(2):397-405. PubMed ID: 32912633
[TBL] [Abstract][Full Text] [Related]
19. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients.
Abrao MS; Surrey E; Gordon K; Snabes MC; Wang H; Ijacu H; Taylor HS
BMC Womens Health; 2021 Jun; 21(1):246. PubMed ID: 34134684
[TBL] [Abstract][Full Text] [Related]
20. The effect of dietary interventions on pain and quality of life in women diagnosed with endometriosis: a prospective study with control group.
van Haaps AP; Wijbers JV; Schreurs AMF; Vlek S; Tuynman J; De Bie B; de Vogel AL; van Wely M; Mijatovic V
Hum Reprod; 2023 Dec; 38(12):2433-2446. PubMed ID: 37877417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
